drugset / Trial / NCT00639522
Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the maximum tolerated dose and pharmacokinetics of liposomal paclitaxel with/without capecitabine in Chinese cancer patients with advanced gastric carcinoma.
Timeline
- Start
- 2008-05
- Primary completion
- 2009-09
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 175 mg/m2 | — |
| Subject | Capecitabine | Small molecule | 185 mg/m2 | — |
| Subject | Capecitabine | Small molecule | 195 mg/m2 | — |
| Subject | Capecitabine | Small molecule | 200 mg/m2 | — |
| Subject | Capecitabine | Small molecule | 205 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 185 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 195 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 200 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 205 mg/m2 | Intravenous |